Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group. Am J Hematol 1995 May;49(1):92-4
Date
05/01/1995Pubmed ID
7741147DOI
10.1002/ajh.2830490117Scopus ID
2-s2.0-0029015187 (requires institutional sign-in at Scopus site) 7 CitationsAbstract
This report summarizes safety and efficacy information among patients treated with high doses (> 75 U/kg) of a monoclonal antibody-purified factor IX concentrate [coagulation factor IX (human) monoclonal antibody purified)] in two clinical trials. One hundred infusions of this factor IX concentrate at doses > 75 U/kg were administered to 35 patients, six of whom had experienced thrombotic complications during previous treatment with prothrombin complex concentrate. Hemostasis in all patients was rated as "excellent," and there were no thrombotic complications.
Author List
Warrier I, Kasper CK, White GC 2nd, Shapiro AD, Bergman GEAuthor
Gilbert C. White MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAntibodies, Monoclonal
Dose-Response Relationship, Drug
Factor IX
Hemostasis
Humans
Thrombosis